Mark A. Velleca
2016 - G1 Therapeutics
In 2016, Mark A. Velleca earned a total compensation of $1.3M as Chief Executive Officer and President at G1 Therapeutics.
Compensation breakdown
| Bonus | $133,650 |
|---|---|
| Option Awards | $788,196 |
| Salary | $405,000 |
| Other | $7,950 |
| Total | $1,334,796 |
Velleca received $788.2K in option awards, accounting for 59% of the total pay in 2016.
Velleca also received $133.7K in bonus, $405K in salary and $8K in other compensation.
Rankings
In 2016, Mark A. Velleca's compensation ranked 6,820th out of 14,075 executives tracked by ExecPay. In other words, Velleca earned more than 51.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,820 out of 14,075 | 52nd |
Division Manufacturing | 2,547 out of 5,489 | 54th |
Major group Chemicals And Allied Products | 829 out of 1,895 | 56th |
Industry group Drugs | 637 out of 1,538 | 59th |
Industry Pharmaceutical Preparations | 504 out of 1,176 | 57th |
Source: SEC filing on April 18, 2018.
News
Black Diamond Therapeutics CEO Mark Velleca receives $2.9M in 2023
April 24, 2024
G1 Therapeutics CEO Mark Velleca's 2020 pay stays at $4M
April 28, 2021
G1 Therapeutics Chief Business Officer Mark Avagliano receives $5.5M in 2019
April 24, 2020
G1 Therapeutics Chief Commercial Officer John Demaree receives $7.5M in 2018
April 30, 2019